Tivozanib hydrochloride monohydrate
Zanaflex, Fotivda (tivozanib hydrochloride) is a small molecule pharmaceutical. Tivozanib hydrochloride was first approved as Zanaflex on 2017-08-24. It has been approved in Europe to treat renal cell carcinoma.
| Trade Name | Fotivda |
|---|---|
| Common Name | Tivozanib hydrochloride monohydrate |
| Indication | renal cell carcinoma |
| Drug Class | Angiogenesis inhibitors |
